Tandem Diabetes Care, Inc., a medical device company, focuses on the design, development, and commercialization of various products for people with insulin-dependent diabetes in the United States. The company offers t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set; t:connect diabetes management application, a PC and Mac-compatible cloud-based data management application that provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and t:flex insulin delivery system that includes 480-unit disposable insulin cartridge and ...
11045 Roselle Street
San Diego, CA 92121
Founded in 2006
Tandem Diabetes Care, Inc. Commences Shipping t:slim Insulin Pump with Updated Software
Apr 20 15
Tandem Diabetes Care, Inc. commenced shipments of t:slim Pumps featuring enhanced software. The updated software, based on customer and healthcare provider feedback, includes an expansion of the reverse correction function, the ability to enter a manual bolus directly in the suggested bolus window, off-pump cartridge filling, and other features to enhance convenience and flexibility. Tandem is actively working on a project to provide current t:slim Pump users the ability to update their pump software remotely, similar to other modern consumer devices. The company plans to submit a filing for this remote update capability to the U.S. Food and Drug Administration later in 2015.
Tandem Diabetes Care, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015
Feb 24 15
Tandem Diabetes Care, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $18,465,000 or $0.78 per basic and diluted share on sales of $17,889,000 against net loss of $23,613,000 or $2.14 per basic and diluted share on sales of $10,245,000 a year ago. Operating loss of $17,502,000 compared to $16,463,000 a year ago. Loss before taxes of $18,394,000 compared to $23,613,000 a year ago.
For the full year, the company reported net loss of $79,524,000 or $3.42 per basic and diluted share on sales of $49,722,000 against net loss of $63,139,000 or $21.46 per basic and diluted share on sales of $29,007,000 a year ago. Operating loss of $75,664,000 compared to $49,434,000 a year ago. Loss before taxes of $79,453,000 compared to $63,139,000 a year ago.
For the year ending December 31, 2015, the company is providing its guidance as follows: sales are estimated to be in the range of $70.0 million to $75.0 million, which includes $1.0 million to $3.0 million of t:flex Insulin Pump sales, and operating margin is estimated to be in the range of negative 100% to negative 110%, which includes approximately $13.0 million to $14.0 million in non-cash stock-based compensation expense.
Tandem Diabetes Care, Inc. to Report Q4, 2014 Results on Feb 24, 2015
Feb 10 15
Tandem Diabetes Care, Inc. announced that they will report Q4, 2014 results After-Market on Feb 24, 2015